Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840548 | 0.89 | CA1 (0.47) | CA1CA2LMNAMAPTMAPK1 | |
| SCHEMBL841540 | 0.89 | CA1 (0.47) | CA1CA2LMNAMAPTMAPK1 | |
| SCHEMBL839434 | 0.86 | MME (0.54) | CA1CA2MAPTMAPK1EPHX2 | |
| SCHEMBL6116952 | 0.84 | CA1 (0.45) | CA1CA2LMNAMAPTMAPK1 | |
| SCHEMBL840454 | 0.81 | PPARG (0.48) | CA1CA2NR1H4EPHX2SMO | |
| SCHEMBL841258 | 0.81 | MMP8 (0.54) | CA1CA2 | |
| SCHEMBL841451 | 0.78 | MMP8 (0.61) | HDAC1HDAC3HDAC2 | |
| SCHEMBL10633050 | 0.74 | MAPT (0.53) | LMNAMAPTMAPK1NR1H4EPHX2 | |
| SCHEMBL13609098 | 0.74 | KMT2A (0.62) | CA1CA2NR1H4EPHX2KMT2A | |
| SCHEMBL840791 | 0.74 | MME (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8143298-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CA1 4380/4885CA2 649/4885LMNA 1341/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CA1 4380/4885CA2 649/4885LMNA 1341/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CA1 4380/4885CA2 649/4885LMNA 1341/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | CA1 3247/4885CA2 1122/4885LMNA 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.